

Welcome to the COVID-CF project in Europe

CF patient registries throughout Europe have collected data about people with CF who become infected with SARS-Cov-2, causing the illness COVID-19.

Countries that contribute annual data to the ECFS Patient Registry (ECFSPR; www.ecfs.eu/ecfspr) were invited to report COVID-19 case data of people with a PCR-confirmed diagnosis of CF. Centres reported data directly to the ECFSPR, and aggregated data was provided by national registries that use their own data-collection system. Here we present centralised, anonymised data.


We have published two peer reviewed scientific articles: one about [the incidence of SARS-Co-V-2 infection in pwCF](#) up to the 30 June 2020 and one about [risk factors for poorer outcomes](#).

The updates presented here are not peer reviewed and should be considered as preliminary.

Summary (up to 4 March 2022)

2652	PCR or antigen-confirmed cases with data available
393	Were hospitalised
61	Needed intensive care

Month of diagnosis with SARS-CoV-2 infection




*Month of diagnosis was unknown for 544 patients

Distribution in Europe

SARS-CoV-2 incidence per 1000 pwCF (up to 4/3/22)

n=2652




Countries in grey not in ECFSPR

Created with Datawrapper


COVID-19 outcomes

Number of patients (n=2652)



Age category (years)


Number of patients (n=2652)



Cystic fibrosis characteristics


Number of patients (n=2652)

Patients could have between 0 and 3 of these characteristics



Percent predicted FEV1

Number of patients (n=1710*)



Note: ppFEV1 = percent predicted forced expiratory volume in one second.

*Percent predicted FEV1 was only calculated for patients aged 6 years and over